Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest Expenses (2016 - 2019)

Fate Therapeutics' Interest Expenses history spans 7 years, with the latest figure at $600000.0 for Q4 2019.

  • For Q4 2019, Interest Expenses rose 38.25% year-over-year to $600000.0; the TTM value through Sep 2020 reached $600000.0, down 63.59%, while the annual FY2019 figure was $1.8 million, 5.88% up from the prior year.
  • Interest Expenses reached $600000.0 in Q4 2019 per FATE's latest filing, up from $400000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $600000.0 in Q4 2019 to a low of $212000.0 in Q2 2017.
  • Average Interest Expenses over 5 years is $424578.9, with a median of $412000.0 recorded in 2017.
  • Peak YoY movement for Interest Expenses: soared 1910.71% in 2015, then plummeted 47.0% in 2017.
  • A 5-year view of Interest Expenses shows it stood at $562000.0 in 2015, then plummeted by 41.46% to $329000.0 in 2016, then increased by 25.23% to $412000.0 in 2017, then rose by 5.34% to $434000.0 in 2018, then soared by 38.25% to $600000.0 in 2019.
  • Per Business Quant, the three most recent readings for FATE's Interest Expenses are $600000.0 (Q4 2019), $400000.0 (Q3 2019), and $409000.0 (Q2 2019).